<DOC>
	<DOCNO>NCT01558739</DOCNO>
	<brief_summary>The primary objective study evaluate efficacy INC424 patient PMF , PPV MF , PET-MF use composite measure either objective endpoint ( &gt; 50 % reduction splenomegaly use palpitation 48 week ) and/or subjective endpoint ( &gt; 50 % reduction total symptom score 48 week ) .</brief_summary>
	<brief_title>Exploratory Phase II Study INC424 Patients With Primary Myelofibrosis ( PMF ) Post Polycythaemia Myelofibrosis ( PPV MF ) Post Essential Thrombocythaemia Myelofibrosis ( PET-MF )</brief_title>
	<detailed_description />
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<mesh_term>Polycythemia</mesh_term>
	<mesh_term>Thrombocytosis</mesh_term>
	<mesh_term>Thrombocythemia , Essential</mesh_term>
	<criteria>Patients must eligible another ongoing INC424 clinical trial . Patients must diagnose PMF , PPV MF PETMF , accord 2008 revised World Health Organization criterion irrespective JAK2 mutation status . Patients PMF require therapy must classify high risk ( 3 prognostic factor ) OR intermediate risk level 2 ( 2 prognostic factor , ) , OR intermediate risk level 1 ( 1 prognostic factor , ) enlarge spleen . The prognostic factor , define International Working Group : 1 . Age &gt; 65 year ; 2 . Presence constitutional symptom ( weight loss , fever , night sweat ) ; mark anemia ( Hgb &lt; 10g/dL ) * ; 3 . Leukocytosis ( history WBC &gt; 25 x109/L ) ; 4 . Circulating blast &gt; 1 % . • A hemoglobin value &lt; 10 g/dL must demonstrate Screening Visit patient transfusion dependent . Patients receive regular transfusion pack red blood cell consider hemoglobin &lt; 10 g/dL purpose evaluation risk factor . Patients Intermediate1 disease splenomegaly must palpable spleen measure 5 cm great costal margin point great splenic protrusion . Patients must peripheral blood blast count &lt; 10 % . Patients adequate liver function define direct bilirubin ≤ 2.0 x ULN ALT ≤ 2.5 x ULN . Patients adequate renal function define serum creatinine ≤ 2 x ULN . Patients ECOG performance status 0 , 1 , 2 ( Appendix 5 ) . Exclusion criterion : Patients eligible hematopoietic stem cell transplantation ( suitable candidate suitable donor available ) . Patients history malignancy past 3 year except treat , earlystage squamous basal cell carcinoma situ . Patients undergoing treatment hematopoietic growth factor receptor agonist ( i.e. , erythropoietin [ Epo ] , granulocyte colony stimulate factor ( GCSF [ Neupogen ; Neulasta ] , romiplostim , eltrombopag ) time within 2 week prior Screening 4 week prior Baseline . Impairment gastrointestinal ( GI ) function GI disease may significantly alter absorption oral INC424 ( e.g. , ulcerative disease , uncontrolled nausea , vomit , diarrhea , malabsorption syndrome , small bowel resection ) . Patients cardiac disease Investigator 's opinion may jeopardize safety patient compliance protocol . Patients clinically significant bacterial , fungal , parasitic viral infection require therapy . Patients acute bacterial infection require antibiotic use delay screening/enrollment course antibiotic therapy complete . Patients know active hepatitis A , B , C HIVpositive . Patients inadequate bone marrow reserve demonstrate : 1 . Absolute neutrophil count ( ANC ) ≤ 1000/µL . 2 . Platelet count &lt; 100,000/µL without assistance growth factor , thrombopoietic factor platelet transfusion . Patients history platelet count &lt; 50,000/µL ANC &lt; 500/µL except treatment myeloproliferative disorder treatment cytotoxic therapy reason . Patients coagulation parameter ( PT , PTT , INR ) ≥ 1.5 . Patients know hypersensitivity INC424 JAK1/2 inhibitor , excipients . Patients ongoing treatment another investigational medication treat investigational medication within 30 day screen . Patients concurrent condition , Investigator 's opinion would jeopardize safety patient compliance protocol . Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Ruxolitinib</keyword>
	<keyword>INC424</keyword>
	<keyword>myelofibrosis</keyword>
	<keyword>PMF</keyword>
	<keyword>post polycythemia myelofibrosis</keyword>
	<keyword>PPV MF</keyword>
	<keyword>post-essential thrombocythemia myelofibrosis</keyword>
	<keyword>PET-MF</keyword>
	<keyword>Primary Myelofibrosis</keyword>
	<keyword>Polycythemia</keyword>
	<keyword>Thrombocythemia</keyword>
	<keyword>Essential Thrombocytosis</keyword>
	<keyword>myeloproliferative Disorders</keyword>
	<keyword>Bone Marrow Diseases</keyword>
	<keyword>Haematologic Diseases</keyword>
	<keyword>Blood Coagulation Disorders</keyword>
	<keyword>Blood Platelet Disorders</keyword>
	<keyword>Haemorrhagic Disorders</keyword>
</DOC>